Apogen Biotechnologies

Breaking drug resistance in cancer through the development of a new class of therapies that target key drivers of ongoing DNA mutation and tumor evolution.


Latest News Entry
ApoGen Biotechnologies Expands Series A Financing to $11 Million and Enhances Leadership Team

M Ventures Joins Existing Investors to Support Development of Novel Therapies Targeting Resistance to Cancer Therapy
Stephen Gwaltney and Peter de Vries Join Senior Scientific Management Team

all portfolio news